Most Popular News Stories on OBR Daily
(ASCO) Apr 17, 2019 - Cancer experts from around the world will gather to share the latest clinical cancer research impacting patient care at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO). Advances in targeted therapies for pancreatic, prostate, and pediatric cancers, as well as new approaches to overcoming limited access to cancer care are among the topics that will be highlighted in the meeting’s official Press Program. The 2019 ASCO Annual Meeting, taking place May 31-June 4 in Chicago, will bring together more than 32,000 oncology professionals from across the globe. The theme of this year’s conference is Caring for Every Patient, Learning From Every Patient.
(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four studies, 14% of all Opdivo-treated patients were alive at four years. Notably, in patients with PD-L1 ≥1% and <1%, four-year overall survival (OS) rates were 19% and 11%, respectively. In the pooled analysis of the two phase 3 trials, CheckMate -017 and -057, the four-year OS rate for Opdivo-treated patients was 14% compared to 5% for docetaxel-treated patients. Additionally, exploratory landmark analysis of OS found that of patients who had a complete or partial response at six months, 58% of those treated with Opdivo were alive four years later vs. 12% of patients treated with docetaxel.
(Science Magazine) Mar 28, 2019 - A patient was one of a growing number of fast-progressing cancer cases that point to a dark side of so-called checkpoint inhibitors. Although the 65-year-old woman had a rare type of endometrial cancer that had spread to her liver and was expected to be fatal, she still felt well enough to work and swim. As a last hope, her doctors gave her a type of immune-stimulating drug that had had near-miraculous results in some patients with advanced cancer. But 3 weeks after she began the drug, the woman's liver tumors had grown, and her abdomen was swollen with tumors as big as oranges.
(ProPublica/New York Times) Apr 4, 2019 - Top officials at Memorial Sloan Kettering Cancer Center repeatedly violated policies on financial conflicts of interest, fostering a culture in which profits appeared to take precedence over research and patient care, according to details released on Thursday from an outside review. The findings followed months of turmoil over executives’ ties to drug and health care companies at one of the nation’s leading cancer centers. The review, conducted by the law firm Debevoise & Plimpton, was outlined at a staff meeting on Thursday morning. It concluded that officials frequently violated or skirted their own policies; that hospital leaders’ ties to companies were likely considered on an ad hoc basis rather than through rigorous vetting; and that researchers were often unaware that some senior executives had financial stakes in the outcomes of their studies.
(COA) Apr 9, 2019 - COA applauds the senate finance committee for PBM hearing as part of national efforts to shed light on PBM abuses and lower drug prices. More investigation and oversight needed to examine adverse impact of PBM abuses on patient care.
(Merck) Apr 11, 2019 - KEYTRUDA now approved for first-line treatment of patients with stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (TPS ≥1%), with No EGFR or ALK genomic tumor aberrations. Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
(Forbes) Apr 3, 2019 - Sorrento Therapeutics has accused billionaire Patrick Soon-Shiong of acquiring a cancer drug that would have competed with the blockbuster drug he invented and preventing it from ever reaching the market, according to a civil complaint filed in Los Angeles Superior Court on Wednesday. In 2015 NantPharma, a subsidiary in Soon-Shiong’s network of Nant companies, acquired the rights to the cancer drug Cynviloq from Sorrento Therapeutics with a $90 million up-front cash payment and agreed to pay an additional $1.2 billion if certain regulatory milestones were reached. At the time Cynviloq was undergoing multiple clinical trials to determine its bioequivalence to Abraxane, a cancer drug Soon-Shiong invented. In 2010 Soon-Shiong had sold the manufacturer of Abraxane, Abraxis, to Celgene in a $4.5 billion stock and cash deal.
(Reuters) Mar 28, 2019 - AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world’s biggest cancer drug maker Roche. The deal on the drug known as trastuzumab deruxtecan sent shares in Japan’s Daiichi soaring 16 percent, its daily limit, to a record high on Friday. Daiichi’s stock has climbed 45 percent this year on optimism about the treatment. Britain’s AstraZeneca plans to use some of the proceeds of a $3.5 billion share issue to fund the deal. Its shares fell as much as 6 percent.
(Seattle Genetics) Mar 28, 2019 - Seattle Genetics, Inc. and Astellas Pharma Inc. today announced positive topline results from the first cohort of patients in a pivotal phase 2 single-arm clinical trial known as EV-201. The cohort is evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received previous treatment with both platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor. Results showed a 44 percent objective response rate (ORR) per blinded independent central review.
(Reuters) Apr 12, 2019 - Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent. The company said its decision to discontinue the trial was based on recommendations of an independent committee, which suggested that the treatment may not provide a meaningful benefit to patients.